Trump Announce Plan: Weight-Loss Drugs Getting Cheaper
Trump is set to roll out a deal with Novo Nordisk and Eli
Lilly, the companies behind the most talked-about weight-loss drugs on the
planet. GLP-1 medications have become a cultural phenomenon, but their sky-high
prices — often $1,000 to $1,350 a month — kept them out of reach for
many.
Now the administration says that’s about to change.
Two major things are happening:
1. Lower prices on Medicare
Novo Nordisk and Eli Lilly will sell their drugs to Medicare
at a “most favored nation” rate. Translation: cheaper prices locked in by
agreement.
Medicare users will also get:
- $50
copay
- Expanded
eligibility
- Coverage
for weight-loss drugs alone if a patient is severely overweight
- Broader
comorbidity rules for others
This is a major policy shift. Until now, Medicare generally
avoided covering weight-loss drugs.
2. Big consumer discounts through TrumpRX
A new platform called TrumpRX, launching in early
2026, will offer major price cuts for regular consumers too.
Officials say:
- Injectable
GLP-1 drugs will start at or below $350, dropping to $245
over two years.
- Oral
versions, once approved, will launch at $149.
- Private
insurance customers (about two-thirds of Americans) will likely see 25%
lower prices as insurers adjust.
One official put it simply: “Everyone’s getting something
here.”
Stunning Price Drops: The Numbers People Are Talking
About
The second article gives even more specific price points —
and they’re eye-catching.
Here’s what’s expected under the TRUMP ANNOUNCEMENT:
- Wegovy
(lowest dose) → $149 on TrumpRX
- Zepbound
(starting dose) → $299 (about $50 cheaper than current
direct-to-consumer prices)
- Ozempic
→ Possibly included later
- Eli
Lilly’s weight-loss pill (orforglipron) → $149, if FDA approves
it
For anyone following GLP-1 trends, this is a huge moment.
These drugs rarely drop below $500 even with coupons. Seeing $149 is
unheard-of.
Why This Deal Happened Now
Let’s break it down.
Trump had been threatening 200% tariffs on
pharmaceutical imports to push for more domestic manufacturing. Drugmakers,
wanting stability, came to the table.
In return for lower prices:
- They
get certainty about tariffs
- They
get millions of new Medicare and Medicaid patients added to their
potential market
- They
avoid pricing battles heading into the next election cycle
It’s a textbook political trade-off: affordability for
voters, predictability for companies.
And affordability is a big deal right now. Analysts say
concerns about rising healthcare costs played a major role in recent Republican
losses in New Jersey and Virginia governor races.
Medicaid, Medicare, Private Insurance — Who Wins?
Pretty much everyone:
Medicare
- Copay
fixed at $50
- Much
wider coverage
- Strong
discounts through TrumpRX
Medicaid
- Will
cover GLP-1s for obesity, not just other medical uses
Commercial insurance users
- At
least 25% lower prices, according to administration estimates
One interesting detail: some insurers may let patients buy
drugs in the cash market and count the spending toward their deductibles.
That’s a big shift.
More Deals Are Coming
This isn’t happening in isolation.
The administration has recently signed agreements with:
- Pfizer
- AstraZeneca
- EMD
Serono
Pfizer even committed $70 billion to U.S.
manufacturing, part of Trump’s push to bring drug production back home.
These lower prices might not hit consumers until 2026, but
the direction is clear: drug costs are becoming a central political
battleground.
What People Should Watch Next
- Whether
orforglipron (Eli Lilly’s pill) gets fast-tracked
- How
quickly insurers adapt to new price structures
- Which
GLP-1 brands get listed on TrumpRX next
- How
this affects voter behavior ahead of the midterms
For now, though, one thing is obvious: the TRUMP ANNOUNCE moment is reshaping the weight-loss drug market in real time.
If you find my content helpful, consider buying me a coffee to show your appreciation and help me continue creating.
Buy Me a Coffee